Vulvovaginal Candidiasis - Pipeline Review, H2 2016

  • ID: 3927215
  • Report
  • 63 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Cidara Therapeutics, Inc.
  • Scynexis, Inc.
  • TGV-Laboratories
  • MORE
Vulvovaginal Candidiasis - Pipeline Review, H2 2016

Summary

‘Vulvovaginal Candidiasis - Pipeline Review, H2 2016’, provides an overview of the Vulvovaginal Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
- The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Cidara Therapeutics, Inc.
  • Scynexis, Inc.
  • TGV-Laboratories
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Vulvovaginal Candidiasis Overview

Therapeutics Development

Pipeline Products for Vulvovaginal Candidiasis - Overview

Vulvovaginal Candidiasis - Therapeutics under Development by Companies

Vulvovaginal Candidiasis - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Vulvovaginal Candidiasis - Products under Development by Companies

Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development

Cidara Therapeutics, Inc.

Grupo Ferrer Internacional, S.A.

NovaDigm Therapeutics, Inc.

Scynexis, Inc.

TGV-Laboratories

Viamet Pharmaceuticals, Inc.

Vulvovaginal Candidiasis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(clotrimazole + diclofenac sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arasertaconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MH-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myc-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDV-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDV-3A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCY-078 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vulvovaginal Candidiasis - Dormant Projects

Vulvovaginal Candidiasis - Discontinued Products

Vulvovaginal Candidiasis - Product Development Milestones

Featured News & Press Releases

Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis

Aug 10, 2016: Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting

Aug 09, 2016: Cidara Therapeutics Announced Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting

Aug 08, 2016: SCYNEXIS Reports Second Quarter 2016 Financial Results and Provides Company Update

Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis

Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016

Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors

May 31, 2016: FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics Novel Antifungal Product Candidate

Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis

Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections

Jan 11, 2016: Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV

Dec 01, 2015: SCYNEXIS Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis

Jul 29, 2015: Viamet to Present at Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting

Apr 24, 2015: Viamet to Provide Update on VT-1161, Novel Antifungal Program at ECCMID 2015

Feb 12, 2015: Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Vulvovaginal Candidiasis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Vulvovaginal Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016

Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016

Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016

Vulvovaginal Candidiasis - Pipeline by Scynexis, Inc., H2 2016

Vulvovaginal Candidiasis - Pipeline by TGV-Laboratories, H2 2016

Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Vulvovaginal Candidiasis - Dormant Projects, H2 2016

Vulvovaginal Candidiasis - Discontinued Products, H2 2016 49List of Figures

Number of Products under Development for Vulvovaginal Candidiasis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Cidara Therapeutics, Inc.
  • Scynexis, Inc.
  • TGV-Laboratories
  • MORE
Vulvovaginal Candidiasis pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. Our latest report Vulvovaginal Candidiasis – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Vulvovaginal Candidiasis Vulvovaginal candidiasis refers to a disorder characterized by signs and symptoms of vulvovaginal inflammation in the presence of Candida species. Symptoms of vulvovaginal candidiasis include itching, soreness and/or burning discomfort in the vagina and vulva, heavy white curd-like vaginal discharge, bright red rash affecting inner and outer parts of the vulva, sometimes spreading widely in the groin to include pubic areas, inguinal areas and thighs. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Cidara Therapeutics, Inc.
Grupo Ferrer Internacional, S.A.
NovaDigm Therapeutics, Inc.
Scynexis, Inc.
TGV-Laboratories
Viamet Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll